170569-86-5

中文名称 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-

英文名称 4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE

CAS 170569-86-5

分子式 C16H11ClF3N3O2S

分子量 401.79

MOL 文件 170569-86-5.mol

更新日期 2024/05/07 11:50:05

170569-86-5 结构式

基本信息物理化学性质安全数据图谱信息 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-价格(试剂级) 常见问题列表

基本信息

中文别名

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-吡唑-1-基)苯磺酰胺

英文别名

SC-236
SC-58236
SC 236 - SC 58236
4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-

物理化学性质

熔点146-148°C

沸点543.4±60.0 °C(Predicted)

密度1.54±0.1 g/cm3(Predicted)

储存条件2-8°C

溶解度二甲基亚砜：>20mg/mL

酸度系数(pKa)9.66±0.10(Predicted)

形态粉末

颜色白色至灰白色

安全数据

危险性符号(GHS)

GHS06

警示词危险

危险性描述H301

防范说明P264-P270-P301+P310-P405-P501

危险品标志T

危险类别码25

安全说明45

危险品运输编号UN 2811 6.1 / PGIII

WGK Germany3

图谱信息

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-(170569-86-5)核磁图(¹HNMR)

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	HY-W010983	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236	170569-86-5	5mg	800元
2024/04/30	HY-W010983	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236	170569-86-5	10mg	1200元
2024/04/30	HY-W010983	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236	170569-86-5	25mg	2500元

常见问题列表

生物活性

SC-236 是具有口服活性的 COX-2 特异性抑制剂 (对 COX-1 的 IC50 值为 10 nM)和 PPARγ 激动剂。SC-236 可通过 c-Jun 氨基端抑制激活蛋白-1 (AP-1) 活性。SC-236在小鼠模型中通过抑制 ERK 的磷酸化发挥抗炎作用。

靶点

COX-2

10 nM (IC ₅₀ )

COX-1

17.8 μM (IC ₅₀ )

体外研究

SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.

Western Blot Analysis

Cell Line:	vECs.
Concentration:	15 μM
Incubation Time:	30 min.
Result:	Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.

Western Blot Analysis

Cell Line:	COS 7 cells.
Concentration:	3 and 10 μM.
Incubation Time:	18 h (combined with 15d-PGJ ₂ ).
Result:	Acted in a concentration-dependent manner as a PPARγ agonist.

体内研究

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.

Animal Model:	Seventy-six male adult Wistar rats weighing 200-220 g (CCl ₄ -treated).
Dosage:	6 mg/kg.
Administration:	Orally, 3 times per week.
Result:	A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats.